Belpharm
Belpharm was established in January 2019 following a foreign investor initiative to develop pharmaceutical manufacturing in Tashkent. By 2023, it had completed its beta-lactam antibiotic and solid dosage production phases.
The company lists 10,000 square metres of production and warehouse space. Its published annual capacities include more than 550 million tablets, 70 million capsules, 10 million sachets and 12 million vials of sterile antibiotic powders.
Belpharm also offers contract manufacturing, enabling partners to use its production infrastructure. Its business combines local manufacturing with European equipment and a quality system covering production and laboratory control.